Fig. 3From: Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT studyKaplan–Meier estimates of OS according to response pattern after application of EORTC. The numbers of patients at risk in each group and for the respective time-points are shown below the plots. cPMD, confirmed progressive metabolic diseaseBack to article page